

# RSC Advances



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This *Accepted Manuscript* will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

In Vitro Evaluation of the Conjugations of Neonicotinoids with Transport Protein:

Photochemistry, Ligand Docking and Molecular Dynamics Studies

Wei Peng,<sup>abc</sup> Fei Ding\*<sup>ad</sup> and Yu-Kui Peng<sup>e</sup>

<sup>a</sup> *College of Agriculture and Plant Protection, Qingdao Agricultural University,*

*Qingdao 266109, China*

<sup>b</sup> *College of Food Science and Engineering, Qingdao Agricultural University,*

*Qingdao 266109, China*

<sup>c</sup> *Department of Chemistry, China Agricultural University, Beijing 100193, China*

<sup>d</sup> *Department of Biological Engineering, Massachusetts Institute of Technology,*

*Cambridge, MA 02139, United States*

<sup>e</sup> *Center for Food Quality Supervision & Testing, Ministry of Agriculture, College of*

*Food Science & Engineering, Northwest A&F University, Yangling 712100, China*

\*Corresponding Author

Phone/fax: +86-29-87092367

E-mail: alexf.ting@outlook.com, feiding@cau.edu.cn

1 **ABSTRACT**

2

3 The main objective of this effort was to assess the biological effects of  
4 neonicotinoids, together with the structure-activity relationships, by employing  
5 plasma albumin as a nontarget model. Fluorescence indicated clearly that static type is  
6 the effective mechanism for the reduction of Trp-214 residue emission when  
7  $c(\text{neonicotinoid}) \leq 10 \mu\text{M}$ , yet both static and dynamic properties occurred in the  
8 system if the concentration is higher than  $10 \mu\text{M}$ . The stoichiometric proportion of the  
9 protein-neonicotinoid is obviously at 1 : 1, and subdomain IIA was discovered to  
10 possess high-affinity for these chemicals. This corroborates molecular docking,  
11 site-directed mutagenesis, molecular dynamics simulation and free energy calculation  
12 laying the neonicotinoids at the warfarin-azapropazone site, and yield hydrogen bonds,  
13  $\pi$ - $\pi$  stacking and hydrophobic interactions with several pivotal amino acid residues,  
14 i.e. Phe-211, Trp-214 and Arg-222. These noncovalent bonds caused partially  
15 conformational changes on protein, that is, the  $\alpha$ -helix content was decreased from  
16 55.9% to 48.5% along with an increase in the  $\beta$ -sheet, turn and random coil, as  
17 derived from synchronous fluorescence and circular dichroism. And this phenomenon  
18 squares well with the outcomes of the assignment of protein secondary structure.  
19 According to the analyses of structure-activity relationships, it can be observed that  
20 the neonicotinoids with the ring-closing structure (part B), e.g. imidacloprid and  
21 thiacloprid, have relatively low affinity toward protein, as compared with some  
22 ring-opening agents such as nitenpyram and acetamiprid. These disparities may be

23 referable to the fact that the ring-opening neonicotinoids hold great flexibility, and  
24 then generate noncovalent interactions with the amino acid residues in the active  
25 cavity more easily. In addition, toxicological relevance of the biorecognitions of  
26 neonicotinoids with biopolymer was also explored herein. Perhaps this exploration  
27 could use as a nontarget biological model for the evaluation of neonicotinoids toxicity  
28 and it might also provide helpful clues for the synthesis of novel neonicotinoids  
29 agents.

30

31 **KEYWORDS:** *neonicotinoids, globular protein, molecular dynamics simulation, free*  
32 *energy calculations, structure-activity relationships, toxicological relevance*

33

34

35

36

37

38

39

40

41

42

43

44

## 45 INTRODUCTION

46

47 Over the last few decades, the development of neonicotinoids as an importantly  
48 novel insecticide represents a milestone in agrochemical research. They are the only  
49 major new class of insecticides developed during these years.<sup>1</sup> For the moment the  
50 commercial neonicotinoids include acetamiprid, clothianidin, dinotefuran,  
51 imidacloprid, nitenpyram, sulfoxaflor, thiacloprid and thiamethoxam. Because of their  
52 low use dose and excellent activities on diverse types of pests, neonicotinoids account  
53 for approximately 20% of the global insecticides market and profit one billion dollars  
54 worldwide per year, especially imidacloprid.<sup>2,3</sup>

55 In fact, previous efforts clearly show that the neonicotinoids have good selectivity  
56 for the nicotinic acetylcholine receptors (nAChRs) in insects.<sup>4,5</sup> Nevertheless,  
57 molecular recognition of these agrochemical compounds to mammals is very  
58 scarce. Regrettably, accumulatively toxicological data indicated that exposure to  
59 neonicotinoids may relate closely with the enriched production of terrible  
60 consequences in animals and perhaps humans.<sup>6-9</sup> Further, the available literatures on  
61 neonicotinoids and their degradation in mammals have demonstrated that some of  
62 them can cause carcinogenesis, hepatotoxicity and probable teratogenicity.<sup>10-12</sup>  
63 Bhardwaj et al.<sup>13</sup> observed moderate pathological changes in female *Rattus norvegicus*  
64 Wistar rats administered 0, 5, 10, and 20 mg/kg/day by feed imidacloprid in corn oil  
65 for 90 days. Bal et al.<sup>14</sup> found that low doses of imidacloprid could lead to the  
66 deterioration in sperm motility and abnormality in sperm morphology in adult male

67 Wistar albino rats. After three months of oral fed of imidacloprid (8.0 mg per  
68 kilogram body weight), the apoptosis of germ cells has increased, and with seminal  
69 DNA fragmentation. Some experiments also proved that a number of widely used  
70 pesticides, including neonicotinoids, might arouse a panic for their probable endocrine  
71 disruptor property, which would eventually produce detrimental outcomes to grow up  
72 reproductive system in humans.<sup>15,16</sup> Moreover, Gawade et al.<sup>17</sup> and Devan et al.<sup>18</sup>  
73 alluded that continuous exposure to imidacloprid and acetamiprid during development  
74 will result in negative effects on immune system, and proposed that caution shall be  
75 taken to protect human beings, in particular, vulnerable persons such as children and  
76 pregnant women, from neonicotinoids.

77 Besides the toxicological problems, nowadays the issues of pesticide residues  
78 have emerged as the great anxiety as well.<sup>19,20</sup> Imidacloprid, which is currently the  
79 most extensively applied neonicotinoid insecticide in the world, has a relatively high  
80 water solubility ( $0.61 \text{ g L}^{-1}$ ) and degrade slowly in the environment.<sup>21</sup> If in soil under  
81 aerobic conditions, it can persist with a half-life ranging from 1 to 3 year and the  
82 content has almost doubled every 5 years since 1990s.<sup>22,23</sup> The widespread residues of  
83 neonicotinoids in the environment may have made matters worse and could induce the  
84 serious hazards to human health directly in the near future. Thereby it is most urgent  
85 that the comprehensive assessment of the toxicological action of neonicotinoids,  
86 notably by employing vitally multifunctional macromolecules such as  
87 enzymes/proteins or nucleic acids as the biological models should be executed.

88 In recent years, except for the *in vivo* experimental approaches, the biological

89 estimation of molecular recognition of various ligands with biopolymers, e.g. DNA,  
90 RNA, polypeptides and proteins is an essential part to receive a good comprehension  
91 of toxicological features.<sup>24,25</sup> Albumin, which is formed in the liver, is the most  
92 abundant protein in blood plasma and contributes nearly half of the blood serum  
93 protein. One of the interestingly biological functions of albumin is to transport  
94 endogenous and exogenous substances such as agrochemicals, bilirubin, colorants,  
95 fatty acids, hormones, metal ions and bioactive compounds.<sup>26,27</sup> Meantime, albumin  
96 account for most of the antioxidant capacity of plasma, and exhibit some types of  
97 enzymatic properties. Consequently, researchers use this protein as an excellent  
98 biomarker to evaluate many diseases involving cancer, ischemia, postmenopausal  
99 obesity and rheumatoid arthritis.<sup>28</sup> In addition, it has the ability to treat several  
100 diseases that might need to monitor the glycemic control. It is commonly accepted  
101 today that the degree of biointeractions between biopolymers and ligands would  
102 govern their absorption and dispersion into cellular tissues, affect their excretion from  
103 the living organism, and eventually influence substance's pharmaceutical and  
104 toxicological roles.<sup>29,30</sup> Thereby the exploration of the potentially adverse effects of  
105 neonicotinoids through utilizing albumin as a target is completely suitable, and this  
106 kind of study could provide pivotal clues in the structural aspects that consider the  
107 overall toxic activities of neonicotinoids.

108 To date many biophysical techniques have been used to check the ligand  
109 recognition events, including calorimetry, chromatography, crystallography,  
110 electrophoresis, equilibrium dialysis, fluorescence, light scattering, nuclear magnetic

111 resonance, surface enhanced Raman spectroscopy, surface tension, ultracentrifugation,  
112 ultrafiltration, etc.<sup>31-33</sup> Among them, fluorescence spectroscopy has been confirmed to  
113 be one of the most integrally qualitative and quantitative ways to analyze the  
114 noncovalent biomacromolecule-ligand reactions.<sup>34</sup> Nonetheless, molecular modeling  
115 can often be used to demonstrate the binding interactions via reasonably  
116 computational calculation, and it is also usually utilized to scrutinize the quantitative  
117 structure-affinity relationships.<sup>35</sup> In two more recently qualitative investigations,  
118 Mikhailopulo et al.<sup>36</sup> and Wang et al.,<sup>37</sup> respectively, probed the interactions between  
119 albumin and imidacloprid by steady-state fluorescence, but these works did not  
120 exposit the reaction essence, binding domain, structural changes, the key noncovalent  
121 bonds and the critical amino acid residues, etc. Very recently, we have preliminarily  
122 explored the biointeractions of imidacloprid and its major metabolites with some  
123 model biopolymers such as albumin from bovine serum, hemoglobin human and  
124 lysozyme from chicken egg white;<sup>38,39</sup> however, the precise recognition features, the  
125 concrete recognition location, conformational transitions, dynamic recognition  
126 processes, the binding free energies, structure-activity relationships of neonicotinoids  
127 and toxicological relevance are yet unresolved. These crucial information, particularly  
128 the dynamic reaction behaviors, may benefit our understanding of the biological  
129 toxicity and biotransformation of neonicotinoids in the human body.

130 Given the above-mentioned background, our current contribution was to  
131 deliberate the recognition nature, stoichiometry, binding location, structural  
132 transitions, dynamic interaction patterns along with the free energy in the presence of



133 neonicotinoids (structure shown in Fig. 1), by the combination of steady-state and  
134 time-resolved fluorescence, chemical denaturation, extrinsic  
135 8-anilino-1-naphthalenesulfonic acid (ANS) probe, circular dichroism (CD), *in silico*  
136 docking, site-directed mutagenesis, molecular dynamics simulation as well as the  
137 decomposition of free energy. Specifically the structural-activity relationships and the  
138 toxicological relevance of neonicotinoids agents were further discussed in this attempt.  
139 Possibly this study will give beneficial understanding on dissecting the toxicological  
140 profiles of neonicotinoids, the relationships of structure and activity and the chemical  
141 essence of biorecognition between neonicotinoids and biological biomacromolecules.

142 Fig. 1 here about

143

## 144 **EXPERIMENTAL**

145

146 **Material.** Albumin from human serum (A3782, lyophilized powder, fatty acid  
147 free, globulin free,  $\geq 99\%$ ), imidacloprid (37894, analytical standard) and  
148 8-anilino-1-naphthalenesulfonic acid (A1028,  $\geq 97\%$ ) employed in this assay were  
149 obtained from Sigma-Aldrich (St. Louis, MO) and utilized without further purification,  
150 and ultrapure water was prepared by a Super-Q<sup>®</sup> Plus Water Purification System from  
151 EMD Millipore Corporation (Billerica, MA). All of the experiments were conducted  
152 in Tris (0.2 M)-HCl (0.1 M) buffer of pH=7.4, with an ionic strength of 0.1 in the  
153 existence of sodium chloride, and the pH was measured with an Orion Star A211 pH  
154 Benchtop Meter (Thermo Scientific, Waltham, MA). Albumin was stored in a

155 refrigerator at  $\sim 277$  K, and dilutions of the albumin stock ( $10 \mu\text{M}$ ) in Tris-HCl  
156 buffer solution were got instantly before application, the concentration of albumin  
157 was determined by the approach of Lowry et al.<sup>40</sup> All other chemicals used were of  
158 analytical reagent and acquired from Sigma-Aldrich.

159 **Steady-State Fluorescence.** Steady-state fluorescence spectra were collected with  
160 a 1.0 cm path length quartz cuvette applying a F-7000 Fluorescence  
161 Spectrophotometer (Hitachi, Japan) outfitted with a thermostatic bath. Both excitation  
162 and emission slits were fixed at 5.0 nm, fluorescence emission spectra were recorded  
163 by exciting the incessantly blended albumin at 295 nm to prefer tryptophan (Trp)  
164 fluorescence, and steady-state fluorescence were registered in the wavelength range of  
165 300~500 nm at a scanning speed of  $240 \text{ nm min}^{-1}$ . The sample of blank involving of  
166 the Tris-HCl buffer solution of imidacloprid in relevant amounts was deducted from  
167 all fluorescence experiments.

168 **Ligand Docking.** Molecular docking of the albumin-neonicotinoids adducts was  
169 operated on SGI Fuel Visual Workstation-550L (Silicon Graphics International Corp.,  
170 Milpitas, CA). The X-ray diffraction crystallographic structure of protein (entry codes  
171 1AO6), solved at a atomic resolution of  $2.5 \text{ \AA}$ ,<sup>41</sup> was repossessed from the Research  
172 Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank  
173 (<http://www.rcsb.org/pdb>). After being input in the commercial software Sybyl  
174 Version 7.3 (<http://www.certara.com>), the structure of protein was thoroughly  
175 examined for atom and bond type exactness allocation. Hydrogen atoms were  
176 theoretically appended utilizing the menus of both Sybyl Biopolymer and Build/Edit.

177 To avert unfavorable amino acid/amino acid interactions and repellent steric conflicts,  
178 positions of hydrogen atoms only were energy minimized with the Powell's conjugate  
179 direction method with 0.05 kcal mol<sup>-1</sup> energy gradient convergence criteria for 1,500  
180 circulations, this action does not alter locations to heavy atoms, and the potential of  
181 the three-dimensional structure of protein was designated based upon the AMBER  
182 force field with Kollman charges. The two-dimensional configurations of  
183 neonicotinoids were obtained from the database of PubChem  
184 (<http://pubchem.ncbi.nlm.nih.gov>), and the original structures of these ligands were  
185 generated by the program of Sybyl 7.3.

186 Meanwhile, both hydrogen atoms and Gasteiger-Hückel partial charges were  
187 added and assigned for each neonicotinoid, respectively, and AM1-BCC charges<sup>42</sup>  
188 were also added to the insecticides imidacloprid and thiacloprid, respectively, in order  
189 to make sure the rationality of the added charges and further compare the differences  
190 between the two docking results. To validate the reasonableness of the initial docking  
191 conformation received by the Sybyl 7.3, the crystal structures contained imidacloprid  
192 (entry codes 3WTL) and thiacloprid (entry codes 3WTJ),<sup>43</sup> respectively, have been  
193 downloaded from the Protein Data Bank, and the ligand molecules gained from the  
194 two crystal structures will directly be docked to albumin. The irrationality of the  
195 original conformation induced by the addition of charges and force fields should be  
196 excluded, and the docking results were expressed in the form of superposition  
197 pictures.

198 The program of AutoDock 4.2,<sup>44</sup> which uses a fully automatic flexible molecular

199 docking algorithm, was employed to evaluate the possible conformation of the ligands  
200 that binds to protein, and then the ligands would be docked to protein by utilizing a  
201 Lamarckian Genetic Algorithm (LGA).<sup>45</sup> A grid box was defined before docking to  
202 cover the entire system involving albumin and neonicotinoids with the size of 126  
203 Å×126 Å×126 Å ( $x \times y \times z$ ) with 0.56 Å grid spacing. A hybrid genetic algorithm  
204 (i.e. LGA) has been used to ascertain the probable ligand binding location on protein.  
205 All the generated conformations after docking were clustered up with tolerance of the  
206 Root-Mean-Square Deviation (RMSD) of 2.0 Å from the structural candidates (20)  
207 with the lowest energy. For each docking procedure, three conformations with the  
208 lowest energy (RMSD<1.0 Å) shall be overlaid so as to select the most suitable  
209 docking conformation. And the computer program of PyMOL  
210 (<http://www.schrodinger.com>), which is a user-sponsored molecular visualization  
211 system, could ultimately be applied to exhibit the *in silico* docking results.

212 **Site-Directed Mutagenesis.** Site-directed mutagenesis processes were  
213 accomplished by utilizing the module of “Mutate Monomers” in Sybyl Version 7.3,  
214 and the Trp-214, Phe-211 and Arg-222 residues in albumin were respectively mutated  
215 to alanine (Ala) residue which has nonaromatic and nonpolar properties. To guarantee  
216 the stability of conformation, the mutated proteins were subjected to 3,000 simplex  
217 minimization steps based on the AMBER force field with Kollman charges. Then the  
218 molecular docking of mutated albumin-imidacloprid was run and the other parameters  
219 were in full agreement with the above native albumin-imidacloprid complexation, and  
220 the mutation results were further validated by using molecular dynamics (MD)

221 simulation.

222 **Molecular Dynamics Simulation and the Decomposition of Free Energies.**

223 MD simulations of the native and mutated albumin-neonicotinoids were carried out  
224 using Gromacs program, version 4.5.5, with the Gromos96 ffG43a1 force field.<sup>46,47</sup>

225 Simulation procedures were executed under physiological conditions (pH=7.4), and  
226 the amino acid residues possessed acidity and basicity were adjusted to the  
227 protonation states at neutrality condition. Initial conformations of albumin and  
228 neonicotinoids were, respectively, taken from the original X-ray diffraction crystal  
229 structure that was measured at 2.5 Å resolution (entry codes 1AO6) and the optimal  
230 structures originated from molecular docking. The topology of albumin was yielded  
231 by Gromacs package directly, whereas neonicotinoids by PRODRG2.5 Server.<sup>48</sup> The  
232 simulation systems were solvated with a periodic cubic box (the volume is  
233  $7.335 \times 6.155 \times 8.119 \text{ nm}^3$ ) filled with TIP3P water molecules and an approximate  
234 number (12) of sodium counterion to neutralize the charge.<sup>49</sup> Totally, there are 51,230  
235 crystallographic solvent molecules, and the shortest distance between the complex  
236 and the edge of the box is set to 10 Å. Simulations were conducted utilizing the  
237 isothermal-isobaric (NPT) ensemble with an isotropic pressure of 1 bar, and the  
238 temperature of the neonicotinoids, albumin and solvent (water and counterion) was  
239 separately coupled to an external bath held at 300 K, using the Berendsen thermostat  
240 with 0.2 ps relaxation time.<sup>50,51</sup> The LINCS algorithm was employed to constrain  
241 bond lengths,<sup>52-54</sup> and the long-range electrostatic interactions beyond 10 Å were  
242 modeled using the Particle Mesh Ewald (PME) method with a grid point density of

243 0.1 nm and an interpolation order of 4.<sup>55,56</sup> A cutoff of 10 Å and 14 Å was used for  
244 Coulomb and van der Waals' interactions, respectively. The MD integration time step  
245 was 2.0 fs and covalent bonds were not constrained, and the system configurations  
246 were saved every 2.0 ps. To decrease the atomic collisions with each other, both  
247 gradient descent and conjugate gradient algorithms were utilized to optimize the  
248 whole system.<sup>57,58</sup> First the solvated starting structure was preceded by a 1,000 step  
249 gradient descent and then by conjugate gradient energy minimization. Subsequently,  
250 100 ps equilibration with position restraints runs to remove possible unfavorable  
251 interactions between solute and solvent, and after thorough equilibration, MD  
252 simulations of the native protein-neonicotinoids and the mutational  
253 protein-neonicotinoid were, respectively, run for 30 ns and 50 ns. Further, the pure  
254 albumin was selected to operate 10 ns time period MD simulation and the outcomes  
255 of simulations were finally manifested via Visual Molecular Dynamics 1.9.2,<sup>59</sup> and  
256 the software Discovery Studio Visualization 4.5 (Accelrys, San Diego, CA) was used  
257 to display the pictures of the MD simulations. The program of Dictionary of Protein  
258 Secondary Structure (DSSP),<sup>60,61</sup> together with the tool of do\_dssp embedded in  
259 Gromacs 4.5.5, was exploited to standardize secondary structure assignment in this  
260 study.

261 Additionally, the binding free energies for these molecular interactions were  
262 computed based on the following relationships:<sup>62,63</sup>

$$263 \quad \Delta G_{bind} = G_{complex} - (G_{protein} + G_{ligand}) \quad (1)$$

$$264 \quad \Delta G_{bind} = \Delta G_{gas} - \Delta G_{sol} \quad (2)$$

265 where

$$266 \quad \Delta G_{gas} = \Delta H_{gas} - T\Delta S \approx \Delta E_{MM} - T\Delta S \quad (3)$$

$$267 \quad \Delta G_{bind} \approx \Delta E_{MM} + \Delta G_{sol} - T\Delta S \quad (4)$$

$$268 \quad \Delta E_{MM} = \Delta E_{internal} + \Delta E_{vdW} + \Delta E_{ele} \quad (5)$$

$$269 \quad \Delta G_{sol} = \Delta G_{GB} + \Delta G_{SA} \quad (6)$$

$$270 \quad G_{SA} = \gamma \times SASA + \beta \quad (7)$$

271 In these equations the binding free energy  $\Delta G_{bind}$  is calculated from the contributions  
 272 of gas phase energy  $\Delta G_{gas}$  and solvation energy  $\Delta G_{sol}$ , where  $\Delta G_{gas}$  is composed of  
 273  $\Delta E_{MM}$  and  $T\Delta S$ . The molecular mechanics energy ( $\Delta E_{MM}$ ) is comprised of the internal  
 274 energy ( $\Delta E_{internal}$ ), the van der Waals' energy ( $\Delta E_{vdW}$ ) and the electrostatic energy  
 275 ( $\Delta E_{ele}$ ). The polar solvation component ( $\Delta G_{GB}$ ) is evaluated using the generalized  
 276 Born method, and the nonpolar solvation component ( $\Delta G_{SA}$ ) is estimated utilizing  
 277 solvent accessible area with the  $\gamma$  parameter set to  $0.00542 \text{ kcal (mol } \text{\AA}^{-1})$  and the  $\beta$   
 278 parameter set to  $0.92 \text{ kcal mol}^{-1}$ , respectively. The Solvent Accessible Surface Area  
 279 (SASA) is calculated using the linear combination of pairwise overlaps (LCPO)  
 280 model. The error bar of the standard error (SE) is reckoned by

$$281 \quad SE = \frac{STD}{\sqrt{N}} \quad (8)$$

282 where STD stands for the standard deviation and  $N$  is the number of trajectory  
 283 snapshots.

284

## 285 RESULTS AND DISCUSSION

286

287 **Tryptophan Fluorescence Studies.** Basically, there are three amino acid residues  
288 with intrinsic fluorescence, i.e. phenylalanine (Phe), tryptophan (Trp) and tyrosine  
289 (Tyr), but only Trp and Tyr are utilized experimentally because their quantum yield is  
290 high enough to present a good fluorescence signal.<sup>65</sup> Therefore, intrinsic fluorescence  
291 of protein is frequently used to measure the association parameter, binding mode and  
292 rate constant of a specific binding equilibrium. To monitor the reaction between  
293 neonicotinoid and albumin, steady-state fluorescence of protein with various  
294 concentrations of neonicotinoid was acquired in Fig. 2. Intrinsic albumin fluorescence  
295 is normally owing to the emission of Trp residue when excited with 295 nm and the  
296 contributions from the Tyr residues could be ignored. Under the experimental  
297 conditions, neonicotinoid shows no fluorescence emission in the range 300~500 nm  
298 which did not interfere with protein fluorescence. Clearly, albumin displays a strong  
299 fluorescence emission peak at 338 nm following an excitation at 295 nm, and its  
300 intensity decreased regularly with the addition of neonicotinoid. These phenomena  
301 indicated that there was conjugation between protein and neonicotinoid, and the  
302 ligand situated in the region where Trp-214 located within or close the lone amino  
303 acid residue.<sup>66</sup> An analogous report has been portrayed by Bekale et al.<sup>67</sup> for the  
304 biorecognition of polyethylene glycols with milk  $\beta$ -lactoglobulin.

305 Fig. 2 here about

306 The sensitivity of indole fluorescence in protein is the central element in the  
307 variety of fluorescence observed between different proteins and ligands, and the study  
308 of fluorescence mechanism has been regarded as an effective method to inspect



309 protein dynamics and conformations. Fluorescence lifetime measurements have thus  
310 been employed to get the existence of disparate and distinctive protein conformations,  
311 and it can offer directly mechanistic information about the time dependence of the  
312 protein-ligand recognition processes. To clarify the essence of the  
313 albumin-neonicotinoid conjugation, the representative fluorescence decay patterns of  
314 protein at various molar ratios of neonicotinoid in Tris-HCl buffer, pH=7.4, are  
315 appeared in Fig. S1 (Supporting Information), and the time-resolved fluorescence  
316 lifetime and their oscillations are also listed in Table 1. Evidently, the fluorescence  
317 decay curves matched nicely to a biexponential function kinetics, which may suggest  
318 the presence of conformers in equilibrium in the folded structure of albumin. As can  
319 be seen from Table 1, a short and a long lifetime is perceived to be  $\tau_1=3.14$  ns and  $\tau_2$   
320  $=7.18$  ns ( $\chi^2=1.09$ ) for protein during the time-resolved fluorescence decay,  
321 respectively; while in the maximum concentration of neonicotinoid, the lifetime  
322 components are  $\tau_1=2.41$  ns and  $\tau_2=6.31$  ns ( $\chi^2=1.03$ ). The biexponential decay in  
323 the present case might be ascribed to a single electronic transition of Trp residue,  
324 which could present as diverse conformational isomers in the protein. Actually, owing  
325 to steric effects between the side chain of Trp residue and the polypeptide backbone,  
326 all rotamers are not entirely possible.<sup>68,69</sup> The quenching group closest to the indole  
327 moiety is the small amino group after protein-neonicotinoid conjugate occurred, as a  
328 result, the rotamer with the maximum population and the fluorescence lifetime of 7.18  
329 ns. Instead, if amino and carbonyl groups close to the indole ring, this rotamer can  
330 hold the small lifetime component of 3.14 ns. The deconvolutions of conformers of

331 protein are restricted to the solution, and the existence of different Trp residue  
332 rotamers has been strictly approved by nuclear magnetic resonance.<sup>70,71</sup> Hence, we  
333 have not tried to assign the separate constituents, but in contrast the average  
334 fluorescence lifetime has been used to gain a qualitative analysis. The average lifetime  
335 of protein reduces from 5.93 ns to 5.49 ns, at different neonicotinoid concentrations,  
336 illustrating evidently that the quenching of albumin Trp residue fluorescence by  
337 neonicotinoid is combined dynamic and static in nature, not just static or dynamic  
338 quenching. These results are in reasonable consonance with our following analyses  
339 based on steady-state fluorescence data by using the Stern-Volmer equation, and a  
340 comparable examination has been indicated by Abou-Zied et al.<sup>72</sup> for the  
341 interpretation of fluorescence quenching of protein in the presence of medicinal  
342 hydroxyquinoline chemicals, namely 6-hydroxyquinoline, 7-hydroxyquinoline and  
343 8-hydroxyquinoline.

344 Table 1 here about

345 To elaborate the fluorescence quenching type, the well-known Stern-Volmer  
346 equation was used for emission data analysis, and the corresponding results fitted  
347 from Fig. 3 are summarized in Table 2. Usually, a linear Stern-Volmer plot is  
348 frequently suggestive of a single kind of fluorophores, all equivalently accessible to  
349 ligand. Intuitively, the Stern-Volmer plot Fig. 3 in such circumstance is an upward  
350 curvature, concave towards the y-axis. This outcome implied plainly that the  
351 fluorophore (Trp-214 residue) may be dwindled both by collision and by complex  
352 formation with the same compound (neonicotinoid). The Stern-Volmer plot seems to

353 be marked off into two periods, that is the concentration of neonicotinoid is less than  
354 or greater than  $10 \mu\text{M}$ . The Stern-Volmer quenching constant  $K_{\text{SV}}$ , in either case, is the  
355 opposite correlated with temperature, patently expressing the biointeraction between  
356 protein and neonicotinoid is controlled by static reaction in low concentration of  
357 ligand ( $\leq 10 \mu\text{M}$ ), whereas both static and dynamic is likely to predominate when the  
358 concentration exceeds  $10 \mu\text{M}$ .

359 Fig. 3 here about

360 Table 2 here about

361 In pharmacology, as well as in toxicology, the association capacity is one of the  
362 most principal indicators when we estimate the potentially pharmacological or  
363 toxicological activities of a ligand such as specific drug or agrochemical for a  
364 biomacromolecule.<sup>31</sup> Knowledge of the recognition affinity has great significance in  
365 realizing of the absorption, distribution and bioavailability and even the quantitative  
366 depiction of dose-response relationship of a ligand.<sup>73</sup> The equation with a number (3)  
367 in Supporting Information has been employed to treat the raw steady-state  
368 fluorescence data, and Fig. S2 indicates the plots of  $\log(F_0 - F)/F$  versus  $\log[Q]$  for  
369 the protein-neonicotinoid mixture at different temperatures and the corresponding  
370 results of  $K$  and  $n$  values were also collected in Table 2. Visibly, the association  
371 constant  $K$  in both low and high concentration of neonicotinoid is reduced with the  
372 rising temperature, which hinted the emerging of a weak adduct in the association  
373 process and the noncovalent conjugate might probably be in part decomposed when  
374 the temperature elevated. A primary cause for this phenomenon is that higher

375 temperature will typically result in the dissociation of weakly bound protein-ligand  
376 adducts, and consequently smaller amounts of static quenching.

377 According to the idea from Dufour and Dangles,<sup>74</sup> and also united several recent  
378 publications on the topic of biopolymer-ligand, e.g. diverse drugs, emodin, flavonoid  
379 and long-chain perfluoroalkyl acids,<sup>75-78</sup> it is quite clear that the complexation of  
380 neonicotinoid with albumin belongs to moderate affinity with respect to the other  
381 strong protein-ligand complexes with association constants ranging from  $10^6$  to  $10^8$   
382  $M^{-1}$ . In the light of the thermodynamic equation  $\Delta G^\circ = -RT \ln K$ , we may compute the  
383 Gibbs free energy  $\Delta G^\circ = -5.67 \text{ kcal mol}^{-1}$  (298 K), which displays that the formation  
384 of protein-neonicotinoid was an exothermic reaction. Moreover, the value of  $n$  is  
385 approximately equal to 1, insinuating the presence of just one single binding site in  
386 protein for neonicotinoid. As noted earlier, a unique quality of intrinsic fluorescence  
387 of albumin is due to the Trp-214 residue at the subdomain IIA, from the value of  $n$ ,  
388 neonicotinoid binding patch most likely close to this aromatic amino acid residue and  
389 yielding fluorescence quenching in the conjugation.

390 To verify the stoichiometry between neonicotinoid and protein estimated from the  
391 above discussion, the method of continuous variation (Job's plot) is adopted here to  
392 determine the stoichiometry. In this approach, the total molar concentration of  
393 neonicotinoid and protein are held fixed, but their molar fractions are varied.<sup>79</sup>  
394 Fluorescence emission spectra that is proportional to complex formation is plotted  
395 *against* the molar fractions of these two components, and the maximum on the plot  
396 corresponds to the stoichiometry of the two species. The Job's plot for

397 protein-neonicotinoid fluorescence at 338 nm upon excitation at 295 nm is shown in  
398 Fig. 4 and, apparently, the  $x$ -coordinate at the maximum in the curve is 0.509. This  
399 supports the 1 : 1 protein-ligand complexation, and is perfectly in harmony with the  
400 above result derived from the double-logarithmic plots.

401 Fig. 4 here about

402 **Structural Alterations.** As has been shown, time-resolved fluorescence indicates  
403 the conformation of albumin is likely to change so as to accommodate neonicotinoid  
404 suitably through noncovalent bonds. The following content will primarily be centered  
405 on the identification of the structural changes of protein in the presence of  
406 neonicotinoid. To begin with, synchronous fluorescence method was used to  
407 characterize the conformation of albumin interfered with neonicotinoid. It contains  
408 parallel scanning of both excitation and emission monochromators whereas keeping a  
409 fixed wavelength gap ( $\Delta\lambda$ ) or constant augmentation of energy ( $\Delta\nu$ ) between them.<sup>80</sup>  
410 In Miller<sup>81</sup> and Burstein et al.<sup>82</sup> pioneering work, when  $\Delta\lambda=15$  nm or 60 nm, the  
411 distinctive characters of Tyr and Trp residues was acquired. Fig. 5 manifests the  
412 spectral intensity of synchronous fluorescence of albumin in Tris-HCl buffer solution  
413 in the existence of various concentrations of neonicotinoid. It is visible that the  
414 maximum fluorescence emission wavelength has a slight red shift at the investigated  
415 concentration range when  $\Delta\lambda=60$  nm, however, almost no shift when  $\Delta\lambda=15$  nm.  
416 The bathochromic effect denotes that the polarity around Trp residue was increased  
417 and the hydrophobicity was decreased. That is to say, neonicotinoid is within easy  
418 reach of the Trp-214 residue, and then has remarkable impact on the Trp-214 residue

419 microenvironment nearby. Nevertheless, the synchronous fluorescence intensity  
420 declined regularly with the addition of neonicotinoid, which further demonstrated the  
421 occurrence of fluorescence quenching in the association reaction.

422 Fig. 5 here about

423 Circular dichroism (CD), particularly far-UV CD is an important tool in structural  
424 biology for examining the folding, kinetics and whether protein-protein or  
425 protein-ligand interactions alter the conformation of protein. If there are any  
426 conformational changes, this event can lead to a spectrum which will differ from the  
427 sum of the individual portions. To quantitative analyze the structural alterations of  
428 globular protein, the experiments of CD spectra of protein in the absence and presence  
429 of insecticide were recorded in Fig. S3 and the components of secondary structures  
430 calculated based on raw CD data also illustrated as follows. The CD curve of albumin  
431 showed two minus bands in the far-UV CD area at 208 nm and 222 nm, feature of  
432  $\alpha$ -helical configuration of globular protein. The sensible clarification is that the  
433 negative peaks between 208 nm and 209 nm and 222 nm and 223 nm are both  
434 originated from  $\pi \rightarrow \pi^*$  and  $n \rightarrow \pi^*$  transition for the peptide bond of  $\alpha$ -helix.<sup>83</sup> Free  
435 protein possess 55.9%  $\alpha$ -helix, 8.1%  $\beta$ -sheet, 11.6% turn and 24.4% random coil,  
436 upon interact with neonicotinoid, decline of  $\alpha$ -helix structure was viewed from 55.9%  
437 free albumin to 48.5% albumin-neonicotinoid complex; whereas increase in  $\beta$ -sheet,  
438 turn and random coil from 8.1%, 11.6% and 24.4% free albumin to 9.2%, 14.2% and  
439 28.1% albumin-neonicotinoid at a molar ratio of albumin to pesticide of 1 : 8. The  
440 decrease of  $\alpha$ -helix with a growth in the  $\beta$ -sheet, turn and random coil interprets the

441 neonicotinoid interacted with some residues of the peptide chain and eventually  
442 produces the disturbance of the albumin three-dimensional structure, e.g. some degree  
443 of biomacromolecule destabilization upon neonicotinoid complexation.<sup>84</sup> These  
444 experimental facts may further attest the previous speculation by Mikhailopulo et al.<sup>36</sup>  
445 that the conformation of protein would be disrupted through the noncovalent  
446 protein-ligand recognition.

447 All of the above measurements and illustrations ratified the biorecognition of  
448 neonicotinoid with albumin aroused conformational perturbations in protein, which  
449 could probably be related to its physiological function. It is worthwhile to note that  
450 the unfolding of albumin in this part does not signify the pesticide caused widespread  
451 destruction of the three-dimensional structure of protein. Because albumin in solution  
452 might usually be deemed as endowing a single shape overall, but it is possibly more  
453 authentic to consider it as an assembly of peristaltic, flexible parts and frequently  
454 altering in conformation via opening and closing of chief fissures.<sup>85,86</sup> With this mode  
455 of alteration, together with many of its amino acid side chains incessantly in motion  
456 on a microscale sphere, all of these make albumin well adapted to soak up or veer out  
457 the many substances such as insecticide that it carries in the human body.

458 **Molecular Docking.** Molecular docking can suitably be used to investigate the  
459 complexation of ligand at the active site of receptor. In the current study, this method  
460 was applied to examine the binding of neonicotinoids at the active domain of protein.  
461 Albumin is one of the most studied model proteins since its high-resolution tertiary  
462 structure has been solved through X-ray diffraction crystallography by He and

463 Carter<sup>87</sup> in 1992. According to the atomic analysis of crystallized albumin, it is a  
464 heart-shaped tridomain protein which consists of 585 amino acid residues, and each  
465 domain is a product of two subdomains that hold conjunct structural motifs. The three  
466 domains, although homologous, have dissimilar ligand binding functions. Prior to  
467 explain the docking results, the influences of the two force fields, i.e.  
468 Gasteiger-Hückel partial charges and AM1-BCC charges, on the outcomes of  
469 molecular docking have been interpreted by using superposition pattern in this text,  
470 and the data are clearly revealed in Fig. 6. The results displayed that the addition of  
471 Gasteiger-Hückel partial charges and AM1-BCC charges has little impact on the  
472 docking results, and the superimposed data also suggested that the optimal  
473 conformations have high comparability. Meantime, via overlaying multiple low  
474 energy conformations in the present four docking systems, we could find some subtle  
475 differences, but undoubtedly, the optimal conformations may satisfactorily be  
476 superimposed on the most low energy conformations which have similar energy with  
477 the best conformations.

478 Fig. 6 here about

479 The best docking energy outcome ( $\Delta G^\circ = -5.87 \text{ kcal mol}^{-1}$ ) of the  
480 protein-imidacloprid adduct is exhibited in Fig. 7. As can be seen from Fig. 7, the two  
481 oxygen atoms of the nitril in imidacloprid can make hydrogen bonds with the  
482 hydrogen atom of amino group and the hydrogen atom of the secondary amine in  
483 Arg-222 residue, and the bond lengths are 2.05 Å and 2.47 Å, respectively.  
484 Furthermore, the molecular distance between the center of the pyridine ring in ligand



485 and the core of the indole ring in Trp-214 and the benzene ring of Phe-211 residues  
486 are 3.14 Å and 3.27 Å, accordingly indicating that distinct  $\pi$ - $\pi$  stacking, which looks  
487 like a “sandwich”, also occurred between albumin and imidacloprid. In the light of  
488 surface modification of protein, we perceived that the entire neonicotinoid is towards  
489 the hydrophobic pocket that is constituted of Phe-211, Trp-214, Ala-215, Leu-219,  
490 Leu-238 and Val-343 residues, confirming that hydrophobic interactions worked  
491 between them. Meanwhile, the optimal docking results of other  
492 protein-neonicotinoids (thiacloprid, nitenpyram and acetamiprid) complexes are  
493 emerged in Fig. 13, and the critical noncovalent interactions would be illuminated in  
494 the following part of structure-activity relationships.

495 Fig. 7 here about

496 Site-directed mutagenesis is a powerful research tool used to study the structure  
497 and function of enzyme/protein, especially some crucial amino acid residues and the  
498 central noncovalent interactions generated by these residues in biopolymer. To further  
499 confirm these key forces in the noncovalent protein-neonicotinoid process, the amino  
500 acid residues – Trp-214, Phe-211 and Arg-222 have been chosen based on the above  
501 explications, and site-directed mutagenesis experiments of these residues will be  
502 conducted herein. In the following content, we describe the mutation of Trp-214  
503 residue in detail, and the phenomena of mutation of Phe-211 and Arg-222 residues  
504 might be elaborated on Supporting Information. The result of mutated  
505 protein-imidacloprid reaction is displayed in Fig. 8, we noticed that the hydrogen  
506 bonds between the oxygen atoms of polar nitril in imidacloprid and the hydrogen

507 atom of the hydroxyl group in Ser-202 residue were clearly weakened, and the bond  
508 lengths are found to be 2.32 Å and 2.84 Å. Meantime, although the  $\pi$ - $\pi$  stacking  
509 disappeared after the mutation of Trp-214 residue, weak hydrophobic interactions  
510 remained in the mutated system, and these residues includes Phe-211, Ala-213,  
511 Ala-214, Ala-215, Leu-219, Leu-238 and Val-343. Significantly, the noncovalent  
512 strength of the whole system has a downward tendency, such evident changes can be  
513 attributed to the mutation of residue tryptophan (Trp) to alanine (Ala), which  
514 decreases obviously the noncovalent interactions between the amino acid residues  
515 situated within the active region and neonicotinoid.

516 Fig. 8 here about

517 **Molecular Dynamics Simulation and Free Energy Calculations.** Molecular  
518 dynamics (MD) simulation capture the behavior of biomacromolecules in full atomic  
519 detail, and this method could thereby help to substantiate the accuracy of the docking  
520 results. Meanwhile, these dynamic data may assist us in seeking the energy changes  
521 of the biopolymer-ligand systems in a short time frame, and then provide important  
522 information for the decomposition of free energies.<sup>88,89</sup> To affirm the conformational  
523 stability of the protein-neonicotinoids under simulated physiological conditions, and  
524 further earn the binding free energies of the noncovalent complexes, MD simulations  
525 were performed for the four protein-ligand conjugates. In the present attempt, the  
526 complexed conformation received from molecular docking was used as the initial  
527 conformation for MD simulation, and the simulation time for the native  
528 protein-neonicotinoids is 30 ns. Nevertheless, the pure protein was also executed 10

529 ns simulation process. Frequently, if the fluctuation of the RMSD value for a typically  
530 dynamic system keeps within 0.1 nm, the system can be regarded as the actualization  
531 of a stably dynamic equilibrium state. It is quite evident from Fig. 9 that the four  
532 noncovalent protein-neonicotinoids adducts might be equilibrated within the time  
533 period of 5,000 ps, whereas the pure protein may reach the equilibrium state at the  
534 time point of 2,000 ps.

535 Fig. 9 here about

536 Nonetheless, MD simulations of the mutated protein-neonicotinoid complexes  
537 have also been executed so as to prove the rationality and stability of binding pattern  
538 regarding the mutated amino acid residues (Trp-214, Phe-211 and Arg-222) on protein  
539 and neonicotinoid. As regards the three mutated systems, that is protein  
540 (Trp-214→Ala-214)-imidacloprid, protein (Phe-211→Ala-211)-imidacloprid and  
541 protein (Arg-222→Ala-222)-imidacloprid, simulation processes have respectively  
542 been conducted with the time length of 50 ns. We can find these mutated  
543 protein-ligand systems could achieve the dynamic equilibrium state before 8,000 ps.  
544 The variation tendency of noncovalent interactions between mutated protein and  
545 neonicotinoid under physiological conditions might be deciphered via the dynamic  
546 data. Fig. 10 denotes the RMSD changes of conformations of molecular docking,  
547 concerning the mutated protein-imidacloprid adducts in the MD simulation.  
548 Apparently, if we mutate Trp-214 residue to Ala residue in the polypeptide chain, the  
549 mutated protein-imidacloprid system began to stabilize in the 1,500 ps. The backbone  
550  $C_{\alpha}$  atoms of mutated protein (black) fluctuates stably at 0.4 nm, and the amplitude is

551 within a range of 0.1 nm; while the RMSD of imidacloprid (red) oscillates at about  
552 0.15 nm, and the undulate range should be within 0.05 nm. As for the other mutated  
553 protein-imidacloprid adducts, i.e. Phe→Ala and Arg→Ala residues, the MD  
554 simulation of these conjugates and careful elucidation of dynamic results may be  
555 revealed on the Supporting Information.

556 Fig. 10 here about

557 To inspect whether the binding conformation in dynamic equilibrium can match  
558 the results of molecular docking, the average conformation between 2,000 ps and  
559 8,000 ps time frame was selected and superimposed on the initial conformation of  
560 MD simulation, and the outcome is presented in Fig. 11. It is very clear that the  
561 original conformation of the mutated protein-neonicotinoid adduct overlaps the  
562 equilibrium conformation completely, and the alterations in binding mode between  
563 mutated protein and neonicotinoid are rather small, the fluctuation of RMSD mainly  
564 roots in the overall translation of the complex. Although there are no obvious changes  
565 in binding style and conformation, it is noteworthy that the downward trends are  
566 observable in hydrogen bonds between Ser-202 residue and imidacloprid. The  
567 equilibrium conformation of MD simulation shows the oxygen atoms of nitril in  
568 imidacloprid could make hydrogen bonds with the hydrogen atom of hydroxyl group  
569 in Ser-202 residue, and the bond lengths are 2.41 Å and 3.15 Å, respectively. This  
570 means that the mutation of Trp-214 residue shall be a trigger for the decrease of  
571 affinity between protein and neonicotinoids, or rather, the residue Trp-214 is  
572 extremely important in the protein-neonicotinoids reactions.

573 Fig. 11 here about

574 Integrative contrast of the recognition characters between native and mutated  
575 protein, we may reasonable draw the conclusion that the mutation of some crucial  
576 amino acid residues such as Trp-214, Phe-211 and Arg-222 will not only evoke the  
577 changes of hydrogen bonds, but also cause the decrease and disappearance of  
578 conjugated effects and hydrophobic interactions. These issues would remarkably  
579 reduce the noncovalent strength between protein and neonicotinoid. Accordingly,  
580 there is no doubt that residues Trp-214, Phe-211 and Arg-222 play an essential role in  
581 the molecular recognition of neonicotinoids by plasma albumin.

582 In the same instant we might allocate the secondary structure constituents of  
583 protein in the native and mutated states by the combination of DSSP and Gromacs  
584 programs, and the results of  $\alpha$ -helix,  $\beta$ -sheet and turn are displayed in Table 3.  
585 Distinctly, secondary structure assignments based on dynamic data suggests that free  
586 protein has a relatively high 54.1%  $\alpha$ -helix, 10.3%  $\beta$ -sheet and 10.7% turn content;  
587 upon imidacloprid complexation, major reduction of  $\alpha$ -helix was observed from  
588 54.1% free protein to 44.3% in protein-imidacloprid, and an increase in the  $\beta$ -sheet  
589 and turn structures was also detected from 10.3% and 10.7% free protein to 12.7%  
590 and 13.5% in protein-imidacloprid, respectively. According to the wet experiments of  
591 far-UV CD, free protein in solution contains 55.9%  $\alpha$ -helix, 8.1%  $\beta$ -sheet and 11.6%  
592 turn, while the secondary structures of protein were changed to 48.5%  $\alpha$ -helix and  
593 9.2%  $\beta$ -sheet and 14.2% turn after imidacloprid interaction. One could find that the  
594 secondary structures estimated from both far-UV CD spectra and MD simulations are

595 closely similar, and consequently this phenomenon testifies that the results of  
596 molecular modeling are fully reliable in the current context.

597 Table 3 here about

598 The free energy is a basic quantity narrating the stability of a system because the  
599 free energy of a system is minimized if the system is at equilibrium with its  
600 environment, thereby evaluating the free energy is highly useful in simulations of  
601 biological systems.<sup>90</sup> Frequently, the method of Molecular Mechanics/Generalized  
602 Born Surface Area (MM/GBSA) has been applied to a variety of biomolecular  
603 computational problems including receptor-ligand recognition.<sup>91,92</sup> According to the  
604 previous data of MD simulations, the calculations of free energy of the last 10 ns  
605 dynamic processes in equilibrium state have been proceeded by employing  
606 MM/GBSA approach, and the time interval is 2.0 ps. As indicated distinctly in Table 4,  
607 the energies derived from the MM/GBSA have some discrepancies with the results  
608 from molecular docking, but the variation trends of energies are in accord with the  
609 analyses of molecular docking, and the sequence is detected to be thiacloprid <  
610 imidacloprid < acetamiprid < nitenpyram. The binding free energy values evinced that  
611 the most favorable interaction energies inhered in the protein-nitenpyram ( $\Delta G_{\text{bind}} = -$   
612  $7.24 \text{ kcal mol}^{-1}$ ), and the differences of the van der Waals' energies ( $\Delta E_{\text{vdW}}$ ) of the  
613 four noncovalent systems are relatively small, whereas the electrostatic energies  
614 ( $\Delta E_{\text{ele}}$ ) have some notable disparities. This may well be the crucial reason that leads to  
615 the generation of free energy differences for the neonicotinoid agents. Comparison  
616 with the hydrophobicity discrepancies between the nonpolar solvation and ligand

617 molecules, one can notice that the stronger the hydrophobicity of the ligand, the lower  
618 the  $\Delta G_{SA}$  value. However, as for the mutated protein-neonicotinoid, the free energies  
619 received from molecular dockings and MD simulations are slightly larger than the  
620 native protein-neonicotinoid adducts. These events further support the former view  
621 that the Trp-214, Phe-211 and Arg-222 residues are vitally important to the  
622 biopolymer-neonicotinoids recognition.

623 Table 4 here about

624 **Structure-activity Relationships.** According to the preceding explorations, the  
625 commercial and potential neonicotinoids are commonly constituted of three structural  
626 elements (structure shown in Fig. 12). Among them, imidacloprid, thiacloprid,  
627 nitenpyram and acetamiprid display some similarity that they all have 4-substituted  
628 chloropyridinyl group in their structure.<sup>2,93,94</sup> However, imidacloprid and thiacloprid  
629 contain heterocyclic spacer in part B, on the contrary, nitenpyram and acetamiprid  
630 include acyclic spacer on the element. Chemically, the modification of substituent  
631 group on B component might hold the potential to affect the biorecognition between  
632 protein and neonicotinoids. To authenticate this point, the neonicotinoids, viz.  
633 thiacloprid, nitenpyram and acetamiprid, have been selected for performing ligand  
634 docking studies, and the best results are exhibited in Fig. 13.

635 Fig. 12 here about

636 Fig. 13 here about

637 Obviously, the free energies of the protein-nitenpyram ( $\Delta G_{bind}/\Delta G_{docking} = -7.24/$   
638  $-6.69$  kcal mol<sup>-1</sup>) and the protein-acetamiprid ( $\Delta G_{bind}/\Delta G_{docking} = -6.50/-6.11$  kcal

639 mol<sup>-1</sup>) are larger than the protein-imidacloprid, one logical explanation is that the  
640 critical noncovalent bonds such as hydrogen bonds between the two  
641 protein-neonicotinoid complexes are stronger than the protein-imidacloprid adduct.  
642 The oxygen atom and the nitrogen atom of nitril and the hydrogen atom of the  
643 secondary amine in the acyclic spacer of nitenpyram, could form hydrogen bonds  
644 with the hydrogen atom of amino group in Arg-222 and the nitrogen atom of the  
645 imidazole ring in His-242 residues, and the bond lengths are, respectively, 2.07 Å,  
646 3.06 Å and 2.28 Å (Fig. 13(A)). This pattern will make the conformation of  
647 nitenpyram more stable at the active cavity on protein molecule. As a result, the  
648 recognition ability of acetamiprid with protein is lower than nitenpyram, but still  
649 better than imidacloprid.

650 With regard to the protein-acetamiprid (Fig. 13(B)), the nitrogen atom of the  
651 cyano group in acetamiprid may yield two hydrogen bonds with the hydrogen atoms  
652 of the amino group and the secondary amine in Arg-222 residue, and the bond lengths  
653 are 2.03 Å and 2.29 Å, respectively. Both bond lengths and affinity supports the  
654 deduction that the toxicity of acetamiprid was greater than its analogous imidacloprid.  
655 While for the protein-thiacloprid ( $\Delta G_{\text{bind}}/\Delta G_{\text{docking}} = -4.22/-5.13$  kcal mol<sup>-1</sup>), which  
656 has the same constituent – heterocyclic group as imidacloprid in B spacer, the reaction  
657 of thiacloprid with protein is worst compared with that with the other neonicotinoids,  
658 and the best recognition profile is also exposed in Fig. 13(C). It is conspicuous that  
659 thiacloprid can not generate hydrogen bond with biomacromolecule, however, the  $\pi$ - $\pi$   
660 stacking existed between the pyridine ring in thiacloprid and the benzene ring in



661 Phe-211 and the indole ring in Trp-214 residues. This event should enable the  
662 neonicotinoid to stay at the functional domain. On the basis of the structure-activity  
663 discussions, we might understand that the two neonicotinoids – nitenpyram and  
664 acetamiprid with acyclic spacer possess higher affinity and larger noncovalent  
665 interactions than imidacloprid and thiacloprid with heterocyclic substituents.

666 Probably these recognition disparities spring from the molecular flexibility of the  
667 neonicotinoids. Actually, the flexibility of heterocyclic segment is less than acyclic  
668 fragment in insecticides, the polar functional groups, that is nitril and cyano groups in  
669 nitenpyram and acetamiprid, respectively, would yield excellent noncovalent bonds  
670 with the surrounding amino acid residues, and in consequence this feature could form  
671 more forceful association interactions, as compared with imidacloprid and thiacloprid.  
672 Such phenomenon can expound the discrepancy of biomolecular recognition of  
673 neonicotinoids by biopolymer, and we also believe that the properties of substituents  
674 in neonicotinoids may act a fundamental role in the macromolecule-pesticide  
675 biorecognition. Furthermore, these issues offers theoretical foundation to our previous  
676 opinion, namely a neonicotinoid with high binding strength to protein shall own a  
677 longer half-life, which can enhance the toxicity of the agrochemical for human health.

678 **Toxicological Relevance.** To explore the relationships between the molecular  
679 structures of the four typical neonicotinoid insecticides and the possibly noxious  
680 effects in great detail, the physicochemical and toxicological data of these  
681 neonicotinoids have been assessed based upon the authoritative tools such as  
682 VEGA,<sup>95</sup> Estimation Program Interface (EPI) Suite and Toxicity Estimation Software

683 Tool (TEST),<sup>96,97</sup> which developed by the European Environment Agency and the U.S.  
684 Environmental Protection Agency, and the results were collected in Table 5. Evidently,  
685 nitenpyram possess strong hydrophilicity, this quality might largely be chalked up to  
686 the ring-opening structure and multiple hydrophilic groups in the neonicotinoid.  
687 While for acetamiprid, this compound still retains the ring-opening structure, but the  
688 hydrophilic groups are limited, so acetamiprid has relatively high hydrophobicity.<sup>98</sup>  
689 Additionally, nitenpyram has both carcinogen and developmental toxicant  
690 characteristics, whereas the other neonicotinoids, that is acetamiprid, imidacloprid and  
691 thiacloprid do not possess both carcinogen and developmental toxicant  
692 simultaneously; conversely, either carcinogen or developmental toxicant could be  
693 given on these neonicotinoids. Such facts are closely associated with the structural  
694 features of neonicotinoids. As we expatiated in the structure-activity studies, the  
695 noncovalent forces between protein and nitenpyram outweigh clearly the other three  
696 neonicotinoids, as nitenpyram contains the representative ring-opening structure and  
697 more polar groups. This research finding should also be unraveled the nitenpyram  
698 may hold greater toxicity and carcinogenicity. Nevertheless, it is worth mentioning  
699 that there are no very forceful correlations among acute toxicity, carcinogenicity and  
700 mutagenicity, that is why nitenpyram has lower LC<sub>50</sub> and LD<sub>50</sub>, but the chronic  
701 toxicity of this neonicotinoid is far higher than that of acetamiprid, imidacloprid and  
702 thiacloprid.

703 Table 5 here about

704 Further, there are several exact evidences that imidacloprid might not be the most

705 toxic analogue among the commercial neonicotinoids, whereas nitenpyram and  
706 acetamiprid may own greater negative impact on the human body than imidacloprid.  
707 The haemato-biochemical and histopathological examinations in male Wistar rats has  
708 demonstrated that administration of acetamiprid for nearly one month will result in  
709 significant increase in alanine transaminase, aspartate transaminase, lactate  
710 dehydrogenase and creatinine kinase level in serum, and obvious decrease in  
711 hemoglobin and total erythrocyte count.<sup>99</sup> Meantime, individual cell necrosis and  
712 karyomegaly were observed in liver, and mild glomerular oedema, congestion and  
713 desquamated epithelial cells were also detected in kidney. As for female Wistar rats,  
714 the *in vivo* hematological study suggested that acetamiprid has adverse effect on  
715 hemopoietic organs in animals via subacute exposure.<sup>100</sup> And, the toxicological  
716 evaluation of imidacloprid noted similar changes in male rats, the result also implied  
717 that imidacloprid can lead to the reduction of acetylcholinesterase activity in brain.  
718 Still, Ford and Casida<sup>93</sup> denoted that the chloropyridinyl neonicotinoid insecticides  
719 are readily metabolized and excreted in male albino Swiss-Webster mice as well. The  
720  $t_{1/2}$  relative to the maximum level is much higher for acetamiprid (>240 min) than  
721 imidacloprid (80 min) and thiacloprid (50 min) in plasma.

722 For mammals, the neonicotinoids will chiefly be complexed with neuronal  
723 nAChR, and such biomolecular interactions may produce several pathological  
724 symptoms, for instance, neuronal apoptosis, differentiation, migration, proliferation  
725 and synapse formation.<sup>101</sup> Recent scientific achievements show that the  
726 neonicotinoids, including imidacloprid and acetamiprid, are absorbed and transported

727 by functional biomolecules (primarily albumin) in the organism, and then pass  
728 through the blood-brain barrier, and eventually bind to the target nAChR.<sup>93,102</sup> In the  
729 meantime the IC<sub>50</sub> values of both imidacloprid and acetamiprid for mammalian  
730 neuronal nAChR are 2,600 nM and 700 nM, respectively, which signify that the  
731 biological effects of acetamiprid for nAChR should evidently be larger than  
732 imidacloprid.<sup>103</sup> In general, a substance with a high protein binding affinity might  
733 possess a long half-life ( $t_{1/2}$ ), which would increase its toxicity. In contrast, a  
734 compound with a low protein binding affinity is restricted in its capacity to perfuse  
735 tissues and reach the location of action. As set forth, the overall noncovalent bond  
736 lengths of the protein-acetamiprid reaction are observed to be smaller than the  
737 protein-imidacloprid. This fact suggested distinctly that the association affinity of the  
738 protein-acetamiprid is higher than the protein-imidacloprid; in other words, the  
739 protein-acetamiprid adducts may exist in the body for quite a long time. In the  
740 circumstances more acetamiprid molecules can be delivered to neuronal nAChR via  
741 the active transporter (albumin) and ultimately engender greater toxic actions. These  
742 proofs shall hold common aspects with our formerly comprehensive explorations, and  
743 a neonicotinoid with more flexibility and could endow great recognition strength to  
744 nontarget biomacromolecules, which would increase its toxicity.

745       Aside from the parent compound of neonicotinoids, we should point out that these  
746 chemicals might be biodegraded by metabolic attack at different moiety. Maybe  
747 several metabolites, in some cases, contribute to the overall toxicities such as  
748 carcinogenesis and hepatotoxicity for mammalian. Recently, an interesting

749 scrutiny is endorsed by Casida<sup>104</sup> who have considered that we may get  
750 opportunities for metabolic selectivity and programmed persistence if we can take the  
751 wide diversity of neonicotinoid substituents into consideration. And finally obtain the  
752 neonicotinoid pesticides that possess selective toxicity to various pests while  
753 relatively safe to human beings and beneficial organisms.

754

## 755 **CONCLUSIONS**

756

757 To sum up, the current scenario unwrap the biorecognition events of the maximum  
758 sold neonicotinoids with the multifunctional albumin by combining experimental and  
759 computational techniques at the molecular scale. Data of fluorescence confirmed that  
760 the decrease of Trp residue emission was originated from a static reaction in low  
761 concentration of neonicotinoid, while both static and dynamic processes operated  
762 when the concentration of neonicotinoid exceed 10  $\mu$ M. The binding strength of  
763 neonicotinoid with protein falls within the range of moderate affinity with the  
764 stoichiometry of 1 : 1, and the noncovalent bonds, such as hydrogen bonds,  $\pi$ - $\pi$   
765 stacking and hydrophobic interactions, are largely responsible for stabilizing the  
766 protein-neonicotinoid adduct. Moreover, GuHCl induced albumin denaturation,  
767 extrinsic ANS fluorescence and site-specific competitive binding experiments were all  
768 suggested that the subdomain IIA, Sudlow's site I, owned high-affinity for the binding  
769 of neonicotinoid to protein. These outcomes are in concert with the molecular docking,  
770 site-directed mutagenesis, MD simulation and the decomposition of free energy

771 placing the neonicotinoids in the warfarin-azapropazone site, and several amino acid  
772 residues, i.e. Phe-211, Trp-214 and Arg-222 have a major role in the noncovalent  
773 recognitions.

774 Time-resolved fluorescence decay illustrates the conformation of protein may be  
775 yielded a slight transformation when neonicotinoid conjugated with protein. This  
776 phenomenon has further been verified by synchronous fluorescence and far-UV CD  
777 that the  $\alpha$ -helix of protein was reduced from 55.9% to 48.5% with an increase in the  
778  $\beta$ -sheet, turn and random coil of the protein-neonicotinoid complex. And the results of  
779 MD simulations validate the trends of conformational alterations in the presence of  
780 neonicotinoids. Based on the structure-activity relationships, it can be assured that the  
781 structural differences in part B of neonicotinoids could affect the recognition capacity  
782 between protein and neonicotinoids. To be more exact, the ring-opening structure will  
783 vest neonicotinoids in greater flexibility, and then it is more likely to produce  
784 noncovalent bonds with amino acid residues during the protein-neonicotinoids  
785 reactions. Perhaps this is the reason that the association abilities of nitenpyram and  
786 acetamiprid with protein are higher than the ring-closing neonicotinoids, e.g.  
787 imidacloprid and thiacloprid. Indeed the protein-neonicotinoids complexes are found  
788 to be related closely to toxicological actions of these agrochemicals. Due to  
789 neonicotinoids are one of the most widely used pesticides, along with the highly  
790 controversial topic at present regarding the possible toxicity of these compounds for  
791 nontarget mammals, we hope this study might offer useful information for  
792 evaluating potentially detrimental effects of the insecticides.

## ASSOCIATED CONTENT

### Supporting Information

Detailed protocols of time-resolved fluorescence and extrinsic ANS displacement, site-specific ligand binding and CD spectra, principles of fluorescence quenching, evaluation of association ability, the discussions of ligand binding domain and the mutations of Phe-211 and Arg-222 residues, and the images of time-resolved fluorescence decays, association constant plot, far-UV CD spectra, fluorescence quenching pictures of albumin and ANS-albumin adduct as well as the colorful pictures of the mutations of Phe-211 and Arg-222 residues.

## AUTHOR INFORMATION

### Corresponding Author

\*E-mail: alexf.ting@outlook.com, feiding@cau.edu.cn. Phone/fax: +86-29-87092367.

## NOTES

The authors declare no competing financial interest.

## ACKNOWLEDGEMENTS

We are greatly indebted to Professor Ulrich Kragh-Hansen of Department of Biomedicine, University of Aarhus, for the precious gift of his doctoral dissertation. We particularly appreciate Dr. Peter Ertl of Novartis Institutes for BioMedical Research (Basel, Switzerland) for his kindly supply of JME Molecular Editor. We thank Editors Jessie Morgan and Allison Holloway of Royal Society of Chemistry, for their warm support during the manuscript processing. Thanks also go to the reviewers of this manuscript for their constructive and insightful suggestions.

#### **ABBREVIATIONS USED**

Ala, alanine; ANS, 8-anilino-1-naphthalenesulfonic acid; Arg, arginine; CD, circular dichroism; DNA, deoxyribonucleic acid; DSSP, Dictionary of Protein Secondary Structure; EPI, Estimation Program Interface; GuHCl, guanidine hydrochloride; HCl, hydrochloric acid; His, histidine; IRF, instrument response function; LCPO, linear combination of pairwise overlaps; Leu, leucine; LGA, Lamarckian Genetic Algorithm; Lys, lysine; MD simulation, molecular dynamics simulation; MM/GBSA, Molecular Mechanics/Generalized Born Surface Area; nAChRs, nicotinic acetylcholine receptors; NPT, isothermal-isobaric; Phe, phenylalanine; PME, Particle Mesh Ewald; R, correlation coefficient; RCSB, Research Collaboratory for Structural Bioinformatics; RMSD, Root-Mean-Square Deviation; RNA, ribonucleic acid; SASA, Solvent Accessible Surface Area; S.D., standard deviation; Ser, serine; TEST, Toxicity



Estimation Software Tool; Tris, tris(hydroxymethyl)aminomethane; Trp, tryptophan; Tyr, tyrosine; UV/vis, ultraviolet-visible spectroscopy; Val, valine; VEGA, Virtual models for property Evaluation of chemicals within a Global Architecture.

## REFERENCES

1. S. C. Kessler, E. J. Tiedeken, K. L. Simcock, S. Derveau, J. Mitchell, S. Softley, J. C. Stout and G. A. Wright, *Nature*, 2015, **521**, 74-76.
2. J. E. Casida and K. A. Durkin, *Annu. Rev. Entomol.*, 2013, **58**, 99-117.
3. M. R. Douglas and J. F. Tooker, *Environ. Sci. Technol.*, 2015, **49**, 5088-5097.
4. T. T. Talley, M. Harel, R. E. Hibbs, Z. Radić, M. Tomizawa, J. E. Casida and P. Taylor, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 7606-7611.
5. P. Jeschke, R. Nauen and M. E. Beck, *Angew. Chem. Int. Ed.*, 2013, **52**, 9464-9485.
6. G. Di Prisco, V. Cavaliere, D. Annoscia, P. Varricchio, E. Caprio, F. Nazzi, G. Gargiulo and F. Pennacchio, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 18466-18471.
7. A. D. Ozsahin, R. Bal and O. Yılmaz, *Toxicol. Res.*, 2014, **3**, 324-330.
8. V. Doublet, M. Labarussias, J. R. de Miranda, R. F. A. Moritz and R. J. Paxton, *Environ. Microbiol.*, 2015, **17**, 969-983.
9. D. Goulson, E. Nicholls, C. Botías and E. L. Rotheray, *Science*, 2015, **347**, DOI: 10.1126/science.1255957.

10. S. L. Carmichael, W. Yang, E. Roberts, S. E. Kegley, A. M. Padula, P. B. English, E. J. Lammer and G. M. Shaw, *Environ. Res.*, 2014, **135**, 133-138.
11. K. V. Vinod, S. Srikant, G. Thiruvikramaprakash and T. K. Dutta, *Am. J. Emerg. Med.*, 2015, **33**, 310.e5-310.e6.
12. P. Bagri, V. Kumar and A. K. Sikka, *Drug Chem. Toxicol.*, 2015, **38**, 342-348.
13. S. Bhardwaj, M. K. Srivastava, U. Kapoor and L. P. Srivastava, *Food Chem. Toxicol.*, 2010, **48**, 1185-1190.
14. R. Bal, G. Türk, M. Tuzcu, O. Yilmaz, T. Kuloglu, R. Gundogdu, S. Gür, A. Agca, M. Ulas, Z. Çambay, Z. Tuzcu, H. Gencoglu, M. Guvenc, A. D. Ozsahin, N. Kocaman, A. Aslan and E. Etem, *J. Environ. Sci. Health B.: Pestic. Food Contam. Agric. Wastes*, 2012, **47**, 434-444.
15. M.-L. Jugan, Y. Levi and J.-P. Blondeau, *Biochem. Pharmacol.*, 2010, **79**, 939-947.
16. N. Hoshi, T. Hirano, T. Omotehara, J. Tokumoto, Y. Umemura, Y. Mantani, T. Tanida, K. Warita, Y. Tabuchi, T. Yokoyama and H. Kitagawa, *Biol. Pharm. Bull.*, 2014, **37**, 1439-1443.
17. L. Gawade, S. S. Dadarkar, R. Husain and M. Gatne, *Food Chem. Toxicol.*, 2013, **51**, 61-70.
18. R. K. S. Devan, P. C. Prabu and S. Panchapakesan, *Drug Chem. Toxicol.*, 2015, **38**, 328-336.
19. W. J. Rea, *J. Nutr. Environ. Med.*, 1996, **6**, 55-124.
20. F. Sánchez-Bayo, *Science*, 2014, **346**, 806-807.

21. J.-L. Brunet, M. Maresca, J. Fantini and L. P. Belzunces, *Toxicol. Appl. Pharmacol.*, 2004, **194**, 1-9.
22. C. A. Hallmann, R. P. B. Foppen, C. A. M. van Turnhout, H. de Kroon and E. Jongejans, *Nature*, 2014, **511**, 341-343.
23. M. M. Kandil, C. Trigo, W. C. Koskinen and M. J. Sadowsky, *J. Agric. Food Chem.*, 2015, **63**, 4721-4727.
24. G. J. Rocklin, S. E. Boyce, M. Fischer, I. Fish, D. L. Mobley, B. K. Shoichet and K. A. Dill, *J. Mol. Biol.*, 2013, **425**, 4569-4583.
25. I. Vayá, V. Lhiaubet-Vallet, M. C. Jiménez and M. A. Miranda, *Chem. Soc. Rev.*, 2014, **43**, 4102-4122.
26. S. Tabassum, W. M. Al-Asbahy, M. Afzal, F. Arjmand and R. H. Khan, *Mol. BioSyst.*, 2012, **8**, 2424-2433.
27. M. Kallubai, A. Rachamalla, D. P. Yeggoni and R. Subramanyam, *Mol. BioSyst.*, 2015, **11**, 1172-1183.
28. M. H. Tarhoni, T. Lister, D. E. Ray and W. G. Carter, *Biomarkers*, 2008, **13**, 343-363.
29. F. Zsila, *Mol. Pharmaceutics*, 2013, **10**, 1668-1682.
30. L. Brülisauer, G. Valentino, S. Morinaga, K. Cam, J. T. Bukrinski, M. A. Gauthier and J.-C. Leroux, *Angew. Chem. Int. Ed.*, 2014, **53**, 8392-8396.
31. M. A. Williams, in *Protein-Ligand Interactions: Methods and Applications*, ed. M. A. Williams and T. Daviter, Humana Press, New York, NY, 2nd edn., 2013, vol. 1008, pages 3-34.

32. K. Shanmugaraj, S. Anandakumar and M. Ilanchelian, *RSC Adv.*, 2015, **5**, 3930-3940.
33. J. Wang, Q. Li, L. J. Yang, Y. J. Zhang, J. Yu, X. F. Zhao, J. B. Zheng, Y. Y. Zhang and X. H. Zheng, *Anal. Methods*, 2015, **7**, 3340-3346.
34. P. C. Hebert and L. A. MacManus-Spencer, *Anal. Chem.*, 2010, **82**, 6463-6471.
35. C. E. Tinberg, S. D. Khare, J. Y. Dou, L. Doyle, J. W. Nelson, A. Schena, W. Jankowski, C. G. Kalodimos, K. Johnsson, B. L. Stoddard and D. Baker, *Nature*, 2013, **501**, 212-216.
36. K. I. Mikhailopulo, T. S. Serchenya, E. P. Kiseleva, Y. G. Chernov, T. M. Tsvetkova, N. V. Kovganko and O. V. Sviridov, *J. Appl. Spectrosc.*, 2008, **75**, 857-863.
37. Y.-q. Wang, B.-p. Tang, H.-m. Zhang, Q.-h. Zhou and G.-c. Zhang, *J. Photochem. Photobiol. B: Biol.*, 2009, **94**, 183-190.
38. F. Ding, W. Peng, J.-X. Diao, L. Zhang and Y. Sun, *J. Agric. Food Chem.*, 2013, **61**, 4497-4505.
39. F. Ding and W. Peng, *J. Photochem. Photobiol. B: Biol.*, 2015, **147**, 24-36.
40. O. H. Lowry, N. J. Rosebrough, A. L. Farr and R. J. Randall, *J. Biol. Chem.*, 1951, **193**, 265-275.
41. S. Sugio, A. Kashima, S. Mochizuki, M. Noda and K. Kobayashi, *Protein Eng.*, 1999, **12**, 439-446.
42. A. Jakalian, D. B. Jack and C. I. Bayly, *J. Comput. Chem.*, 2002, **23**, 1623-1641.
43. M. Ihara, T. Okajima, A. Yamashita, T. Oda, T. Asano, M. Matsui, D. B. Sattelle

- and K. Matsuda, *Mol. Pharmacol.*, 2014, **86**, 736-746.
44. G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell and A. J. Olson, *J. Comput. Chem.*, 2009, **30**, 2785-2791.
45. G. M. Morris, D. S. Goodsell, R. S. Halliday, R. Huey, W. E. Hart, R. K. Belew and A. J. Olson, *J. Comput. Chem.*, 1998, **19**, 1639-1662.
46. S. Pronk, S. Páll, R. Schulz, P. Larsson, P. Bjelkmar, R. Apostolov, M. R. Shirts, J. C. Smith, P. M. Kasson, D. van der Spoel, B. Hess and E. Lindahl, *Bioinformatics*, 2013, **29**, 845-854.
47. L. D. Schuler, X. Daura and W. F. van Gunsteren, *J. Comput. Chem.*, 2001, **22**, 1205-1218.
48. A. W. Schüttelkopf and D. M. F. van Aalten, *Acta Crystallogr. Sect. D: Biol. Crystallogr.*, 2004, **60**, 1355-1363.
49. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey and M. L. Klein, *J. Chem. Phys.*, 1983, **79**, 926-935.
50. H. J. C. Berendsen, J. P. M. Postma, W. F. van Gunsteren, A. DiNola and J. R. Haak, *J. Chem. Phys.*, 1984, **81**, 3684-3690.
51. A. D. Nola, H. J. C. Berendsen and O. Edholm, *Macromolecules*, 1984, **17**, 2044-2050.
52. R. Edberg, D. J. Evans and G. P. Morriss, *J. Chem. Phys.*, 1986, **84**, 6933-6939.
53. A. Baranyai and D. J. Evans, *Mol. Phys.*, 1990, **70**, 53-63.
54. B. Hess, H. Bekker, H. J. C. Berendsen and J. G. E. M. Fraaije, *J. Comput. Chem.*, 1997, **18**, 1463-1472.

55. T. Darden, D. York and L. Pedersen, *J. Chem. Phys.*, 1993, **98**, 10089-10092.
56. T. Darden, L. Perera, L. P. Li and L. Pedersen, *Structure*, 1999, **7**, R55-R60.
57. J. A. Snyman, *Practical Mathematical Optimization: An Introduction to Basic Optimization Theory and Classical and New Gradient-Based Algorithms*, Springer Science+Business Media, New York, NY, 2005.
58. M. R. Hestenes and E. Stiefel, *J. Res. Natl. Bur. Stand.*, 1952, **49**, 409-436.
59. W. Humphrey, A. Dalke and K. Schulten, *J. Mol. Graph.*, 1996, **14**, 33-38.
60. W. Kabsch and C. Sander, *Biopolymers*, 1983, **22**, 2577-2637.
61. W. G. Touw, C. Baakman, J. Black, T. A. H. te Beek, E. Krieger, R. P. Joosten and G. Vriend, *Nucleic Acids Res.*, 2015, **43**, D364-D368.
62. M. R. Shirts and D. L. Mobley, in *Biomolecular Simulations: Methods and Protocols*, ed. L. Monticelli and E. Salonen, Humana Press, New York, NY, 2013, vol. 924, pp 271-311.
63. J. E. Kerrigan, in *In Silico Models for Drug Discovery*, ed. S. Kortagere, Humana Press, New York, NY, 2013, vol. 993, pp 95-113.
64. J. Weiser, P. S. Shenkin and W. C. Still, *J. Comput. Chem.*, 1999, **20**, 217-230.
65. M. R. Eftink, in *Topics in Fluorescence Spectroscopy: Protein Fluorescence*, ed. J. R. Lakowicz, Kluwer Academic Publishers, New York, NY, 2002, vol. 6, pp 1-15.
66. M. Zolfagharzadeh, M. Pirouzi, A. Asoodeh, M. R. Saberi and J. Chamani, *J. Biomol. Struct. Dyn.*, 2014, **32**, 1936-1952.
67. L. Bekale, P. Chanphai, S. Sanyakamdhorn, D. Agudelo and H. A. Tajmir-Riahi, *RSC Adv.*, 2014, **4**, 31084-31093.

68. O. J. Rolinski, A. Martin and D. J. S. Birch, *Ann. N. Y. Acad. Sci.*, 2008, **1130**, 314-319.
69. L. Brancalion, *Adv. Protein Chem. Struct. Biol.*, 2013, **93**, 95-152.
70. J. M. Beechem and L. Brand, *Annu. Rev. Biochem.*, 1985, **54**, 43-71.
71. S. L. C. Moors, A. Jonckheer, M. D. Maeyer, Y. Engelborghs and A. Ceulemans, *Curr. Protein Pept. Sci.*, 2008, **9**, 427-446.
72. O. K. Abou-Zied, N. Al-Lawatia, M. Elstner and T. B. Steinbrecher, *J. Phys. Chem. B*, 2013, **117**, 1062-1074.
73. S. Agatonovic-Kustrin, D. W. Morton, L. Truong and S. Razic, *Comb. Chem. High Throughput Screen.*, 2014, **17**, 879-890.
74. C. Dufour and O. Dangles, *Biochim. Biophys. Acta – Gen. Subj.*, 2005, **1721**, 164-173.
75. N. A. Kratochwil, W. Huber, F. Müller, M. Kansy and P. R. Gerber, *Biochem. Pharmacol.*, 2002, **64**, 1355-1374.
76. P. Sevilla, J. M. Rivas, F. García-Blanco, J. V. García-Ramos and S. Sánchez-Cortés, *Biochim. Biophys. Acta – Proteins Proteomics*, 2007, **1774**, 1359-1369.
77. H. N. Bischel, L. A. MacManus-Spencer and R. G. Luthy, *Environ. Sci. Technol.*, 2010, **44**, 5263-5269.
78. A. Bolli, M. Marino, G. Rimbach, G. Fanali, M. Fasano and P. Ascenzi, *Biochem. Biophys. Res. Commun.*, 2010, **398**, 444-449.
79. E. J. Olson and P. Bühlmann, *J. Org. Chem.*, 2011, **76**, 8406-8412.

80. J. B. F. Lloyd, *Nat. Phys. Sci.*, 1971, **231**, 64-65.
81. J. N. Miller, *Analyst*, 1984, **109**, 191-198.
82. E. A. Burstein, N. S. Vedenkina and M. N. Ivkova, *Photochem. Photobiol.*, 1973, **18**, 263-279.
83. N. J. Greenfield, *Methods Enzymol.*, 2004, **383**, 282-317.
84. A. J. S. Jones, *Adv. Drug Deliv. Rev.*, 1993, **10**, 29-90.
85. F. R. N. Gurd and T. M. Rothgeb, *Adv. Protein Chem.*, 1979, **33**, 73-165.
86. A. D. Vogt and E. D. Cera, *Biochemistry*, 2013, **52**, 5723-5729.
87. X. M. He and D. C. Carter, *Nature*, 1992, **358**, 209-215.
88. A. Cavalli, A. Spitaleri, G. Saladino and F. L. Gervasio, *Acc. Chem. Res.*, 2015, **48**, 277-285.
89. R. Buonfiglio, M. Recanatini and M. Masetti, *ChemMedChem*, 2015, **10**, 1141-1148.
90. J. Wereszczynski and J. A. McCammon, *Q. Rev. Biophys.*, 2012, **45**, 1-25.
91. I. Slynko, M. Scharfe, T. Rumpf, J. Eib, E. Metzger, R. Schüle, M. Jung and W. Sippl, *J. Chem. Inf. Model.*, 2014, **54**, 138-150.
92. M. Lundborg and E. Lindahl, *J. Phys. Chem. B*, 2015, **119**, 810-823.
93. K. A. Ford and J. E. Casida, *Chem. Res. Toxicol.*, 2006, **19**, 944-951.
94. M. Tomizawa, D. Maltby, T. T. Talley, K. A. Durkin, K. F. Medzihradzsky, A. L. Burlingame, P. Taylor and J. E. Casida, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 1728-1732.
95. <http://www.vega-qsar.eu/>



96. <http://www.epa.gov/opptintr/exposure/pubs/episuite.htm>
97. <http://www.epa.gov/nrmrl/std/qsar/qsar.html>
98. E. Taillebois, Z. Alamiddine, C. Brazier, J. Graton, A. D. Laurent, S. H. Thany and J.-Y. Le Questel, *Bioorg. Med. Chem.*, 2015, **23**, 1540-1550.
99. [http://www2.epa.gov/sites/production/files/documents/rmpp\\_6thed\\_final\\_lowresopt.pdf](http://www2.epa.gov/sites/production/files/documents/rmpp_6thed_final_lowresopt.pdf)
100. S. Mondal, R. C. Ghosh, M. Mate and C. K. Ghosh, *Environ. Ecol.*, 2009, **27**, 1767-1769.
101. J. Kimura-Kuroda, Y. Komuta, Y. Kuroda, M. Hayashi and H. Kawano, *PLoS ONE*, 2012, **7**, e32432.
102. M. Tomizawa, *Adv. Insect Physiol.*, 2013, **44**, 63-99.
103. L. P. Sheets, A. A. Li, D. J. Minnema, R. H. Collier, M. R. Creek and R. C. Peffer, *Crit. Rev. Toxicol.*, 2015, DOI: 10.3109/10408444.2015.1090948.
104. J. E. Casida, *Environ. Health Perspect.*, 2012, **120**, 487-493.

Table 1

Fluorescence lifetime of albumin as a function of concentrations of imidacloprid

Samples	$\tau_1$ (ns)	$\tau_2$ (ns)	$A_1$	$A_2$	$\tau$ (ns)	$\chi^2$
Free albumin	3.14	7.18	0.31	0.69	5.93	1.09
Albumin+imidacloprid (1 : 1)	3.02	7.02	0.29	0.71	5.86	1.01
Albumin+imidacloprid (1 : 2)	2.75	6.73	0.26	0.74	5.70	1.15
Albumin+imidacloprid (1 : 4)	2.41	6.31	0.21	0.79	5.49	1.03

Table 2

Stern-Volmer quenching constants and association constants for the conjugation of imidacloprid with albumin at different temperatures

<i>T</i> (K)	<i>c</i> (imidacloprid) ≤ 10 μM					<i>c</i> (imidacloprid) > 10 μM				
	<i>K</i> <sub>SV</sub> (× 10 <sup>4</sup> M <sup>-1</sup> )	<i>R</i> <sup>a</sup>	<i>K</i> (× 10 <sup>4</sup> M <sup>-1</sup> )	<i>n</i>	<i>R</i> <sup>a</sup>	<i>K</i> <sub>SV</sub> (× 10 <sup>4</sup> M <sup>-1</sup> )	<i>R</i> <sup>a</sup>	<i>K</i> (× 10 <sup>4</sup> M <sup>-1</sup> )	<i>n</i>	<i>R</i> <sup>a</sup>
298	5.005	0.9853	1.442	0.90	0.9995	8.647	0.9813	116.9	1.27	0.9975
304	4.227	0.9887	0.5559	0.83	0.9996	8.146	0.9962	19.50	1.12	0.9956
310	3.491	0.9946	0.4989	0.83	0.9961	6.457	0.9821	9.977	1.08	0.9973

<sup>a</sup> *R* is the correlation coefficient.

Table 3  
Secondary structure assignment of native and mutated albumin allocated via DSSP method

Samples	Secondary structure elements (%)			RMSD (nm)	
	$\alpha$ -Helix	$\beta$ -Sheet	Turn	Backbone	Ligand
Albumin	54.1	10.3	10.7	0.305	—
Albumin + imidacloprid	44.3	12.7	13.5	0.352	0.086
Albumin + thiacloprid	43.5	13.8	14.1	0.337	0.112
Albumin + nitenpyram	48.2	15.6	11.8	0.321	0.144
Albumin + acetamiprid	46.1	14.2	12.2	0.346	0.108
Albumin (Trp-214→Ala-214) + imidacloprid	41.8	13.3	15.6	0.409	0.095
Albumin (Phe-211→Ala-211) + imidacloprid	44.0	11.9	14.2	0.363	0.201
Albumin (Arg-222→Ala-222) + imidacloprid	42.7	15.1	12.8	0.339	0.114

Table 4

The decomposition of free energies ( $\text{kcal mol}^{-1}$ ) for the albumin-neonicotinoids conjugates through the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) approach

Systems	$\Delta E_{\text{ele}}$	$\Delta E_{\text{vdW}}$	$-T\Delta S$	$\Delta G_{\text{SA}}$	$\Delta G_{\text{GB}}$	$\Delta G_{\text{bind}}$	$\Delta G_{\text{bind}}$ (docking)
Albumin + imidacloprid	$-36.32 \pm 0.27$	$-22.91 \pm 0.12$	$16.39 \pm 0.11$	$-3.44 \pm 0.05$	$38.15 \pm 0.57$	$-6.13$	$-5.87$
Albumin + thiacloprid	$-33.41 \pm 0.15$	$-21.08 \pm 0.03$	$15.57 \pm 0.78$	$-4.61 \pm 0.03$	$35.31 \pm 1.06$	$-4.22$	$-5.13$
Albumin + nitenpyram	$-40.73 \pm 0.33$	$-23.15 \pm 0.27$	$23.21 \pm 1.21$	$-3.08 \pm 0.10$	$36.51 \pm 0.63$	$-7.24$	$-6.69$
Albumin + acetamiprid	$-37.94 \pm 0.29$	$-23.63 \pm 0.06$	$21.02 \pm 1.17$	$-2.77 \pm 0.04$	$36.60 \pm 0.52$	$-6.50$	$-6.11$
Albumin (Trp-214 → Ala-214) + imidacloprid	$-34.22 \pm 0.21$	$-20.02 \pm 0.05$	$14.99 \pm 0.38$	$-3.13 \pm 0.04$	$36.68 \pm 0.25$	$-5.70$	$-5.28$
Albumin (Phe-211 → Ala-211) + imidacloprid	$-34.37 \pm 0.19$	$-19.30 \pm 0.13$	$18.27 \pm 0.24$	$-3.06 \pm 0.10$	$33.14 \pm 0.39$	$-5.32$	$-4.99$
Albumin (Arg-222 → Ala-222) + imidacloprid	$-31.48 \pm 0.12$	$-21.36 \pm 0.48$	$18.45 \pm 0.21$	$-3.50 \pm 0.22$	$31.88 \pm 0.46$	$-6.01$	$-5.54$

Table 5  
 Biochemical parameters of neonicotinoids reckoned based on quantitative structure-activity relationship

Biochemical parameters	Neonicotinoids			
	Imidacloprid	Nitenpyram	Acetamiprid	Thiacloprid
$\log K_{ow}$ (293 K) <sup>a</sup>	(0.57) <sup>h</sup>	(-0.66) <sup>h</sup>	(0.80) <sup>h</sup>	(1.26) <sup>h</sup>
Carcinogenicity <sup>b</sup>	Non-carcinogen	Carcinogen	Carcinogen	Carcinogen
Developmental toxicity <sup>c</sup>	Developmental toxicant	Developmental toxicant	Developmental non-toxicant	Developmental non-toxicant
Fathead minnow LC <sub>50</sub> (96 h) (mg L <sup>-1</sup> ) <sup>d</sup>	108.89	71.47	27.64	4.13
Mutagenicity <sup>e</sup>	Positive	Positive	Positive	Positive
Oral rat LD <sub>50</sub> (mg kg <sup>-1</sup> ) <sup>f</sup>	369.01 (409.93) <sup>h</sup>	954.59 (1576.04) <sup>h</sup>	678.93	1232.67 (444.32) <sup>h</sup>
Ready biodegradability <sup>g</sup>	Non ready biodegradable	Non ready biodegradable	Non ready biodegradable	Non ready biodegradable

<sup>a</sup> From Estimation Program Interface (EPI) Suite.


<sup>b,d,g</sup> From VEGA.

<sup>c,e,f</sup> From Toxicity Estimation Software Tool (TEST), Consensus method.

<sup>h</sup> Experimental data from Estimation Program Interface (EPI) Suite and Toxicity Estimation Software Tool (TEST), respectively.

### Graphic for Table of Contents

Both the flexibility of ligand structures and the property of substituents in neonicotinoids play a pivotal role in the functional protein-neonicotinoids recognitions, and this kind of biointeraction may possess great impacts on the collectively potential toxicity of these widely used agrochemicals.



**Figure Captions:**

Fig. 1. Molecular structures of imidacloprid (A), thiacloprid (B), nitenpyram (C) and acetamiprid (D).

Fig. 2. Fluorescence emission spectra of albumin ( $1.0 \mu\text{M}$ ) at  $\lambda_{\text{ex}}=295 \text{ nm}$  in the presence of different concentrations of imidacloprid.  $c(\text{imidacloprid})=0, 2.0, 4.0, 6.0, 8.0, 10, 12, 14, 16$  and  $18 \mu\text{M}$  (a→j), (x)  $18 \mu\text{M}$  imidacloprid only;  $\text{pH}=7.4, T=298 \text{ K}$ . The insert shows fluorescence quenching extent of albumin, plotted as extinction of intensity ( $F/F_0$ ) against imidacloprid concentrations correspond to the fluorescence emission spectra. All data were corrected for imidacloprid fluorescence and each point was the mean of three independent observations  $\pm$  S.D. ranging  $1.07\% \sim 4.39\%$ .

Fig. 3. Stern-Volmer plot describing fluorescence quenching of albumin ( $1.0 \mu\text{M}$ ) at  $\text{pH}=7.4$  in the presence of different concentrations of imidacloprid. Fluorescence intensity was read at  $\lambda_{\text{ex}}=295 \text{ nm}$ , and the emission maximum occurred at  $338 \text{ nm}$ . Each data was the average of three separate determinations  $\pm$  S.D. ranging  $0.25\% \sim 4.69\%$ .

Fig. 4. Job's plot for albumin-imidacloprid fluorescence based on the method of continuous variation ( $\text{pH}=7.4, T=298 \text{ K}$ ). All data were corrected for imidacloprid fluorescence and each point was the mean of three respective measurements  $\pm$  S.D.



ranging 0.13%~4.99%.

Fig. 5. Synchronous fluorescence intensity of albumin ( $1.0 \mu\text{M}$ ) at  $\text{pH}=7.4$ ,  $T=298 \text{ K}$ , plotted as extinction of albumin Tyr and Trp residues ( $F/F_0$ ) versus imidacloprid concentration. Each data was the mean of three autonomous detections  $\pm$  S.D. ranging 0.46%~2.86%.

Fig. 6. Superposition of the molecular docking results. Albumin showed in surface colored in light pink, and the ball-and-stick model displays neonicotinoids, colored as per the atoms; (A) orange and blue stick model exhibits the optimal skeletal structure of the binding conformation of imidacloprid with the Gasteiger-Hückel partial charges and the AM1-BCC charges, respectively, blue stick model reveals the skeletal structure of the optimal conformation received by using the ligand from crystal structure (entry codes 3WTL) as the initial conformation; (B) wheat and blue stick model indicates the optimal skeletal structure of the binding conformation of thiacloprid with the Gasteiger-Hückel partial charges and the AM1-BCC charges, respectively, blue stick model hints the skeletal structure of the optimal conformation obtained by utilizing the ligand from crystal structure (entry codes 3WTJ) as the initial conformation; (C) cyan stick model suggests the optimal skeletal structure of the binding conformation of nitenpyram with the Gasteiger-Hückel partial charges; and (D) magenta stick model alludes the optimal skeletal structure of the binding conformation of acetamiprid with the Gasteiger-Hückel partial charges; white stick

model depicts the skeletal structures of the two low energy conformations which have the closest energy with the optimal conformation. (For clarification of the references to color in this figure legend, the reader is referred to the web version of the article.)

Fig. 7. Molecular docking of imidacloprid docked to albumin. Albumin displayed in surface colored in light pink, and the ball-and-stick model shows imidacloprid, colored as per the atoms and the key amino acid residues around imidacloprid have been narrated in stick model; salmon stick model implies hydrogen bonds between Arg-222 residue and imidacloprid; green stick model represents  $\pi$ - $\pi$  stacking between Phe-211 and Trp-214 residues and imidacloprid; yellow stick model describes hydrophobic interactions between Phe-211, Trp-214, Ala-215, Leu-219, Leu-238, Val-343 residues and imidacloprid. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)

Fig. 8. Molecular docking of imidacloprid docked to mutated albumin (Trp-214→Ala), the ball-and-stick model portrays imidacloprid, colored as per the atoms and critical amino acid residues around imidacloprid have been denoted in stick model; salmon and yellow stick model hints hydrogen bonds and hydrophobic interactions between mutated albumin and imidacloprid, respectively. (For explanation of the references to color in this figure legend, the reader is referred to the web version of the article.)

Fig. 9. Calculated Root-Mean-Square Deviation (RMSD) from the neonicotinoids and the backbone  $C_{\alpha}$  atoms of albumin from MD simulations at temperature of 298 K with respect to their docking results as a function of the simulation time. The red and black, green and olive, cyan and blue, and magenta and pink trajectories illustrate RMSD values for imidacloprid, thiacloprid, acetamiprid, nitenpyram and the backbone  $C_{\alpha}$  atoms of mutated protein, respectively. The wine trajectory expresses RMSD data for the backbone  $C_{\alpha}$  atoms of pure protein.

Fig. 10. Calculated Root-Mean-Square Deviation (RMSD) from the imidacloprid and the backbone  $C_{\alpha}$  atoms of mutated albumin from MD simulations at temperature of 298 K with respect to their docking results as a function of the simulation time. The red and black (Trp-214→Ala), green and olive (Phe-211→Ala), and cyan and blue (Arg-222→Ala) trajectories symbolize RMSD values for imidacloprid and the backbone  $C_{\alpha}$  atoms of mutated protein, respectively.

Fig. 11. Superposition of the mean conformation of MD simulation on the original conformation of molecular docking resulting from mutated albumin-imidacloprid complex. Protein explained in surface colored in blue green (initial) and pink (average), respectively, and the original and average conformations of imidacloprid delivered in cyan and hot pink ball-and-stick model. The green and pink stick model addresses respectively the initial and average conformations of the crucial amino acid residues involved in the mutated albumin-imidacloprid reaction process. (For

interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)

Fig. 12. Commercial neonicotinoids constituting of three structural components (A, B and C) and the molecular structures of imidacloprid, thiacloprid, nitenpyram and acetamiprid.

Fig. 13. Molecular docking of nitenpyram (A), acetamiprid (B) and thiacloprid (C) docked to albumin. Albumin exhibited in surface colored in light pink, and the ball-and-stick model reveals neonicotinoids, colored as per the atoms and the key amino acid residues around neonicotinoids have been manifested in stick model; salmon stick model discloses hydrogen bonds between Arg-222, His-242 (Panel (A)) and Arg-222 (Panel (B)) residues and nitenpyram and acetamiprid, respectively; green stick model uncovers  $\pi$ - $\pi$  stacking between Phe-211 and Trp-214 residues and neonicotinoids; yellow stick model unveils hydrophobic interactions between Phe-211, Trp-214, Ala-215, Leu-219, Leu-238, Val-343 residues and neonicotinoids. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)




Fig. 1




Fig. 2




Fig. 3




Fig. 4






Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12






Fig. 13